Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) infection, is now a pandemic. Patients who are elderly, immunocompromised, or have comorbidities such as diabetes and hypertension, are at high-risk of COVID-19 mortality. Children are regarded as low-risk because severe respiratory failure occurred in only three among 171 cases (1.75%) in the beginning of 2020 in China.1 Severe COVID-19 cases in children have seldom been reported, even for individuals with childhood cancer or leukemia.2 Here, we report a SARS-CoV-2-positive girl coincidentally diagnosed with acute B-cell acute lymphoblastic leukemia (B-ALL).

A previously healthy 6-year-old girl complained of back pain and gradually became dyssthetic. After 2 weeks she developed additional symptoms, (e.g., paresthesia, remittent fever, and nasal bleeding), requiring hospital admission. On admission (day 1), her laboratory findings revealed pancytopenia: white-blood-cell count of $3.77 \times 10^9$ cells/L, neutropenia ($0.3 \times 10^9$ cells/L), anemia (Hb, 7.0 g/dL), thrombocytopenia ($17 \times 10^9$ cells/L), and elevated lactate dehydrogenase (952 IU/L) and uric acid (6.8 mg/dL) levels. C-reactive protein was also detected (4.55 mg/dL). No hepatomegaly or lymphadenopathy was observed. Piperacillin-tazobactam administration was started from day 1; however, because her blood culture was positive for Staphylococcus aureus, the antibiotic treatment was changed to meropenem from day 2. The nasopharyngeal swab sample was SARS-CoV-2-positive by real-time polymerase chain reaction (PCR) and favipiravir administration was started from day 2. Radiography showed a thoracolumbar vertebral compression fracture that was responsible for her neurological symptoms. However, computed tomography (CT) of the lungs showed no abnormal finding suggestive of pneumonia. Her mother was SARS-CoV-2 PCR-negative; the other family members were not tested. Abnormal lymphoblasts emerged in her peripheral blood and acute leukemia was suspected. She was transferred to our hospital on day 8, where she and her mother were isolated in special wards for SARS-CoV-2-infected patients.

On day 15, the patient had her first SARS-CoV-2 PCR-negative result, and a follow-up examination on day 17 also yielded negative results. She was then transferred to the pediatric ward. Bone marrow examination revealed 100% of lymphoblasts as positive for CD10, 19, 20, 22, 34, 58, cytoplasmic CD79a, KORSA-3544, HLA-DR, cytoplasmic IgM, and terminal deoxynucleotidyl transferase. Chimeric gene screening was negative and the chromosomal analysis showed a normal karyotype.

Prednisolone administration began on day 32, and her response was good. On day 46, a follow-up SARS-CoV-2 PCR was negative, and she showed no COVID-19 symptoms during induction chemotherapy for B-ALL. She achieved complete remission after induction therapy. Her clinical and therapeutic course is shown in Figure 1.

Patients with ALL commonly show an immunosuppressed status at diagnosis, and infections such as bacteremia, respiratory tract infection, viral infection, and fungal infection are
major causes of death during remission induction chemotherapy. Our patient’s case was complicated by staphylococcus bacteremia and SARS-CoV-2 infection at the time of B-ALL diagnosis. We repeatedly confirmed PCR-negative status to avoid worsening of the SARS-CoV-2 infection because there are some cases that become PCR-positive again after having been negative once. In addition, she could become a super-spreader following chemotherapy and corticosteroids use. So, we decided to perform a bone marrow examination and delayed chemotherapy. Fortunately, she tolerated almost 30 days of only supportive therapy because the abnormal lymphoblast proliferation was indolent, and the residual neutrophils and suitable antibiotics were able to resolve the bacteremia. Favipiravir, a polymerase inhibitor developed for treating influenza, has been used for treating COVID-19 in Japan; however, its effect against COVID-19 is still under evaluation in clinical trials. Here, the relatively high amounts of normal lymphocytes in her peripheral blood might have contributed to clearing the SARS-CoV-2 virus. By postponing chemotherapy, we successfully prevented COVID-19 in this case.

Although severe respiratory failure in an 8-year-old Chinese boy with T-cell ALL (T-ALL) has been reported, the details are not published in English. A French group discussed what to do if an ALL patient is diagnosed with SARS-CoV-2 infection. They recommended the ceasing and/or postponing of all chemotherapies, according to the ALL severity. We were able to safely manage our patient by postponing the induction chemotherapy because she had low-risk ALL, with no hyperleukocytosis, renal dysfunction, or disseminated intravascular coagulation. Corticosteroid use for treating COVID-19 is still controversial.

Pediatric patients with laboratory-confirmed COVID-19 tend to have mild or asymptomatic cases, even when they are immunocompromised; however, precautions should still be taken to prevent COVID-19. In a recent report, 30% of pediatric patients with laboratory-confirmed COVID-19 showed no clinical manifestation and had negative chest CT findings. Therefore, laboratory-confirmed COVID-19 is not equal to COVID-19, and the infectivity of such cases is still unknown. Further information on cases of COVID-19 in patients with childhood cancers is needed.
Acknowledgments
We thank Drs. Hiroyuki Kabutoya, Dai Yamamoto, Kotoe Iesato, and Takeshi Tsugawa for supporting our clinical practice. We also thank Katie Oakley, PhD, from Edanz Group (https://en-author-services.edanzgroup.com/) for editing a draft of this manuscript.

Disclosure
The authors declare no conflict of interest.

Author contributions
M.Y., Y.A., K.I., and T.H. treated the patient. M.Y. and Y.K. wrote the manuscript. All authors read and approved the final manuscript.

Informed consent
Written informed consent to publish the findings was obtained from the patient’s mother.

References
1 Lu X, Zhang L, Du H et al. SARS-CoV-2 infection in children. N. Engl. J. Med. 2020; 382: 1663–5.
2 Zhao Y, Zhao W, Wang A et al. First case of coronavirus disease in childhood leukemia in China. Pediatr. Infect. Dis. J. 2020; 39: e142–e145. https://doi.org/10.1097/INF.0000000000002742
3 Baruchel A, Bertrand Y, Boissel N et al. COVID-19 and acute lymphoblastic leukemias of children and adolescents: first recommendations of the leukemia committee of the French society for the fight against cancers and leukemias in children and adolescents (SFCE). Bull. Cancer 2020; 107: 629–32.
4 Baruchel A, Bertrand Y, Boissel N et al. Flash survey on SARS-CoV-2 infections in pediatric patients on anti-cancer treatment. Eur. J. Cancer. 2020; 132: 11–6.
5 Hrusak O, Kalina T, Wolf J et al. CT features of coronavirus disease (COVID-19) in 30 pediatric patients. Am. J. Roentgenol. 2020; 215:1–9.